O	0	3	The	The	DT	B-NP
O	4	12	tyrosine	tyrosine	NN	I-NP
O	13	19	kinase	kinase	NN	I-NP
O	20	29	inhibitor	inhibitor	NN	I-NP
O	30	39	cediranib	cediranib	NN	I-NP
O	40	46	blocks	block	VBZ	B-VP
O	47	53	ligand	ligand	NN	B-NP
O	53	54	-	-	HYPH	O
O	54	61	induced	induce	VBN	B-NP
O	62	70	vascular	vascular	JJ	I-NP
O	71	82	endothelial	endothelial	JJ	I-NP
O	83	89	growth	growth	NN	I-NP
O	90	96	factor	factor	NN	I-NP
O	97	105	receptor	receptor	NN	I-NP
O	105	106	-	-	HYPH	B-NP
O	106	107	3	3	CD	I-NP
O	108	116	activity	activity	NN	I-NP
O	117	120	and	and	CC	I-NP
O	121	138	lymphangiogenesis	lymphangiogenesis	NN	I-NP
O	138	139	.	.	.	O

B-Cancer	140	145	Solid	Solid	JJ	B-NP
I-Cancer	146	152	tumors	tumor	NNS	I-NP
O	153	160	express	express	VBP	B-VP
O	161	162	a	a	DT	B-NP
O	163	168	range	range	NN	I-NP
O	169	171	of	of	IN	B-PP
O	172	179	factors	factor	NNS	B-NP
O	180	188	required	require	VBN	B-VP
O	189	191	to	to	TO	B-VP
O	192	199	sustain	sustain	VB	I-VP
O	200	205	their	their	PRP$	B-NP
O	206	212	growth	growth	NN	I-NP
O	213	216	and	and	CC	O
O	217	224	promote	promote	VBP	B-VP
O	225	230	their	their	PRP$	B-NP
O	231	244	dissemination	dissemination	NN	I-NP
O	244	245	.	.	.	O

O	246	251	Among	Among	IN	B-PP
O	252	257	these	these	DT	B-NP
O	258	261	are	be	VBP	B-VP
O	262	270	vascular	vascular	JJ	B-NP
O	271	282	endothelial	endothelial	JJ	I-NP
O	283	289	growth	growth	NN	I-NP
O	290	296	factor	factor	NN	I-NP
O	296	297	-	-	HYPH	B-NP
O	297	298	A	A	NN	I-NP
O	299	300	(	(	(	O
O	300	304	VEGF	VEGF	NN	B-NP
O	304	305	-	-	HYPH	B-NP
O	305	306	A	A	NN	I-NP
O	306	307	)	)	)	O
O	307	308	,	,	,	O
O	309	312	the	the	DT	B-NP
O	313	316	key	key	JJ	I-NP
O	317	327	angiogenic	angiogenic	JJ	I-NP
O	328	337	stimulant	stimulant	NN	I-NP
O	337	338	,	,	,	O
O	339	342	and	and	CC	O
O	343	347	VEGF	VEGF	NN	B-NP
O	347	348	-	-	HYPH	I-NP
O	348	349	C	C	NN	I-NP
O	349	350	,	,	,	O
O	351	352	a	a	DT	B-NP
O	353	360	primary	primary	JJ	I-NP
O	361	369	mediator	mediator	NN	I-NP
O	370	372	of	of	IN	B-PP
O	373	390	lymphangiogenesis	lymphangiogenesis	NN	B-NP
O	390	391	.	.	.	O

O	392	397	Small	Small	JJ	B-NP
O	398	406	molecule	molecule	NN	I-NP
O	407	415	tyrosine	tyrosine	NN	I-NP
O	416	422	kinase	kinase	NN	I-NP
O	423	433	inhibitors	inhibitor	NNS	I-NP
O	434	439	offer	offer	VBP	B-VP
O	440	443	the	the	DT	B-NP
O	444	453	potential	potential	NN	I-NP
O	454	456	to	to	TO	B-VP
O	457	464	inhibit	inhibit	VB	I-VP
O	465	469	more	more	JJR	B-NP
O	470	474	than	than	IN	I-NP
O	475	478	one	one	CD	I-NP
O	479	485	kinase	kinase	NN	I-NP
O	486	489	and	and	CC	O
O	490	496	impede	impede	VBP	B-VP
B-Cancer	497	502	tumor	tumor	NN	B-NP
O	503	509	growth	growth	NN	I-NP
O	510	512	by	by	IN	B-PP
O	513	521	multiple	multiple	JJ	B-NP
O	522	532	mechanisms	mechanism	NNS	I-NP
O	532	533	.	.	.	O

O	534	541	However	However	RB	B-ADVP
O	541	542	,	,	,	O
O	543	548	their	their	PRP$	B-NP
O	549	556	potency	potency	NN	I-NP
O	557	563	toward	toward	IN	B-PP
O	564	574	individual	individual	JJ	B-NP
O	575	582	targets	target	NNS	I-NP
O	583	586	can	can	MD	B-VP
O	587	591	vary	vary	VB	I-VP
O	591	592	.	.	.	O

O	593	602	Cediranib	Cediranib	NN	B-NP
O	603	604	(	(	(	O
O	604	612	RECENTIN	RECENTIN	NN	B-NP
O	612	613	;	;	:	O
O	614	621	AZD2171	AZD2171	NN	B-NP
O	621	622	)	)	)	O
O	623	625	is	be	VBZ	B-VP
O	626	628	an	an	DT	B-NP
O	629	638	inhibitor	inhibitor	NN	I-NP
O	639	641	of	of	IN	B-PP
O	642	646	VEGF	VEGF	NN	B-NP
O	647	656	signaling	signaling	NN	I-NP
O	657	661	that	that	WDT	B-NP
O	662	665	has	have	VBZ	B-VP
O	666	670	been	be	VBN	I-VP
O	671	676	shown	show	VBN	I-VP
O	677	679	in	in	IN	B-PP
O	680	692	experimental	experimental	JJ	B-NP
O	693	699	models	model	NNS	I-NP
O	700	702	to	to	TO	B-VP
O	703	710	prevent	prevent	VB	I-VP
O	711	715	VEGF	VEGF	NN	B-NP
O	715	716	-	-	HYPH	B-NP
O	716	717	A	A	NN	I-NP
O	717	718	-	-	HYPH	B-NP
O	718	725	induced	induce	VBN	I-NP
O	726	738	angiogenesis	angiogenesis	NN	I-NP
O	739	742	and	and	CC	O
B-Cancer	743	750	primary	primary	JJ	B-NP
I-Cancer	751	756	tumor	tumor	NN	I-NP
O	757	763	growth	growth	NN	I-NP
O	763	764	,	,	,	O
O	765	768	yet	yet	RB	O
O	769	772	the	the	DT	B-NP
O	773	780	effects	effect	NNS	I-NP
O	781	783	of	of	IN	B-PP
O	784	793	cediranib	cediranib	NN	B-NP
O	794	796	on	on	IN	B-PP
O	797	801	VEGF	VEGF	NN	B-NP
O	802	810	receptor	receptor	NN	I-NP
O	811	812	(	(	(	O
O	812	817	VEGFR	VEGFR	NN	B-NP
O	817	818	)	)	)	O
O	818	819	-	-	HYPH	B-NP
O	819	820	3	3	CD	I-NP
O	820	821	-	-	HYPH	I-NP
O	821	829	mediated	mediate	VBN	I-NP
B-Cell	830	841	endothelial	endothelial	JJ	I-NP
I-Cell	842	846	cell	cell	NN	I-NP
O	847	855	function	function	NN	I-NP
O	856	859	and	and	CC	I-NP
O	860	877	lymphangiogenesis	lymphangiogenesis	NN	I-NP
O	878	881	are	be	VBP	B-VP
O	882	889	unknown	unknown	JJ	B-ADJP
O	889	890	.	.	.	O

O	891	893	To	To	TO	B-VP
O	894	900	better	well	RBR	I-VP
O	901	911	understand	understand	VB	I-VP
O	912	915	the	the	DT	B-NP
O	916	924	activity	activity	NN	I-NP
O	925	927	of	of	IN	B-PP
O	928	937	cediranib	cediranib	NN	B-NP
O	938	945	against	against	IN	B-PP
O	946	951	VEGFR	VEGFR	NN	B-NP
O	951	952	-	-	HYPH	B-NP
O	952	953	3	3	CD	I-NP
O	954	957	and	and	CC	O
O	958	961	its	its	PRP$	B-NP
O	962	972	associated	associate	VBN	I-NP
O	973	982	signaling	signaling	NN	I-NP
O	983	989	events	event	NNS	I-NP
O	990	998	compared	compare	VBN	B-PP
O	999	1003	with	with	IN	B-PP
O	1004	1007	its	its	PRP$	B-NP
O	1008	1016	activity	activity	NN	I-NP
O	1017	1024	against	against	IN	B-PP
O	1025	1030	VEGFR	VEGFR	NN	B-NP
O	1030	1031	-	-	HYPH	B-NP
O	1031	1032	2	2	CD	I-NP
O	1032	1033	,	,	,	O
O	1034	1036	we	we	PRP	B-NP
O	1037	1041	used	use	VBD	B-VP
O	1042	1045	the	the	DT	B-NP
O	1046	1054	receptor	receptor	NN	I-NP
O	1054	1055	-	-	HYPH	B-NP
O	1055	1063	specific	specific	JJ	I-NP
O	1064	1071	ligands	ligand	NNS	I-NP
O	1072	1076	VEGF	VEGF	NN	I-NP
O	1076	1077	-	-	HYPH	B-NP
O	1077	1078	E	E	NN	I-NP
O	1079	1082	and	and	CC	I-NP
O	1083	1087	VEGF	VEGF	NN	I-NP
O	1087	1088	-	-	HYPH	B-NP
O	1088	1093	C156S	C156S	NN	I-NP
O	1093	1094	.	.	.	O

O	1095	1097	In	In	IN	B-PP
O	1098	1103	human	human	JJ	B-NP
B-Cell	1104	1115	endothelial	endothelial	JJ	I-NP
I-Cell	1116	1121	cells	cell	NNS	I-NP
O	1121	1122	,	,	,	O
O	1123	1132	cediranib	cediranib	NN	B-NP
O	1133	1142	inhibited	inhibit	VBD	B-VP
O	1143	1147	VEGF	VEGF	NN	B-NP
O	1147	1148	-	-	HYPH	B-NP
O	1148	1149	E	E	NN	I-NP
O	1149	1150	-	-	HYPH	B-NP
O	1150	1157	induced	induce	VBN	I-NP
O	1158	1173	phosphorylation	phosphorylation	NN	I-NP
O	1174	1176	of	of	IN	B-PP
O	1177	1182	VEGFR	VEGFR	NN	B-NP
O	1182	1183	-	-	HYPH	B-NP
O	1183	1184	2	2	CD	I-NP
O	1185	1188	and	and	CC	O
O	1189	1193	VEGF	VEGF	NN	B-NP
O	1193	1194	-	-	HYPH	B-NP
O	1194	1199	C156S	C156S	NN	I-NP
O	1199	1200	-	-	HYPH	O
O	1200	1207	induced	induce	VBN	B-NP
O	1208	1223	phosphorylation	phosphorylation	NN	I-NP
O	1224	1226	of	of	IN	B-PP
O	1227	1232	VEGFR	VEGFR	NN	B-NP
O	1232	1233	-	-	HYPH	B-NP
O	1233	1234	3	3	CD	I-NP
O	1235	1237	at	at	IN	B-PP
O	1238	1252	concentrations	concentration	NNS	B-NP
O	1253	1255	of	of	IN	B-PP
O	1257	1261	less	less	JJR	B-NP
O	1262	1266	than	than	IN	B-PP
O	1267	1268	/	/	SYM	B-NP
O	1268	1269	=	=	SYM	B-VP
O	1269	1274	1nmol	1nmol	NN	B-NP
O	1274	1275	/	/	SYM	O
O	1275	1276	L	L	NN	B-NP
O	1277	1280	and	and	CC	O
O	1281	1290	inhibited	inhibit	VBD	B-VP
O	1291	1301	activation	activation	NN	B-NP
O	1302	1304	of	of	IN	B-PP
O	1305	1315	downstream	downstream	JJ	B-NP
O	1316	1325	signaling	signal	VBG	I-NP
O	1326	1335	molecules	molecule	NNS	I-NP
O	1335	1336	.	.	.	O

O	1337	1349	Additionally	Additionally	RB	B-ADVP
O	1349	1350	,	,	,	O
O	1351	1360	cediranib	cediranib	NN	B-NP
O	1361	1368	blocked	block	VBD	B-VP
O	1369	1373	VEGF	VEGF	NN	B-NP
O	1373	1374	-	-	HYPH	B-NP
O	1374	1379	C156S	C156S	NN	I-NP
O	1379	1380	-	-	HYPH	B-NP
O	1380	1387	induced	induce	VBN	I-NP
O	1388	1391	and	and	CC	I-NP
O	1392	1396	VEGF	VEGF	NN	I-NP
O	1396	1397	-	-	HYPH	B-NP
O	1397	1398	E	E	NN	I-NP
O	1398	1399	-	-	HYPH	B-NP
O	1399	1406	induced	induce	VBN	I-NP
O	1407	1420	proliferation	proliferation	NN	I-NP
O	1420	1421	,	,	,	O
O	1422	1430	survival	survival	NN	B-NP
O	1430	1431	,	,	,	O
O	1432	1435	and	and	CC	O
O	1436	1445	migration	migration	NN	B-NP
O	1446	1448	of	of	IN	B-PP
B-Cell	1449	1458	lymphatic	lymphatic	JJ	B-NP
O	1459	1462	and	and	CC	I-NP
B-Cell	1463	1468	blood	blood	NN	I-NP
I-Cell	1469	1477	vascular	vascular	JJ	I-NP
I-Cell	1478	1489	endothelial	endothelial	JJ	I-NP
I-Cell	1490	1495	cells	cell	NNS	I-NP
O	1495	1496	.	.	.	O

O	1497	1499	In	In	FW	B-ADVP
O	1500	1504	vivo	vivo	FW	I-ADVP
O	1504	1505	,	,	,	O
O	1506	1515	cediranib	cediranib	NN	B-NP
O	1516	1517	(	(	(	O
O	1517	1518	6	6	CD	B-NP
O	1519	1521	mg	mg	NN	I-NP
O	1521	1522	/	/	SYM	B-NP
O	1522	1524	kg	kg	NN	I-NP
O	1524	1525	/	/	SYM	B-NP
O	1525	1526	d	d	NN	I-NP
O	1526	1527	)	)	)	O
O	1528	1537	prevented	prevent	VBD	B-VP
O	1538	1550	angiogenesis	angiogenesis	NN	B-NP
O	1551	1554	and	and	CC	I-NP
O	1555	1572	lymphangiogenesis	lymphangiogenesis	NN	I-NP
O	1573	1580	induced	induce	VBN	B-VP
O	1581	1583	by	by	IN	B-PP
O	1584	1588	VEGF	VEGF	NN	B-NP
O	1588	1589	-	-	HYPH	B-NP
O	1589	1590	E	E	NN	I-NP
O	1590	1591	-	-	HYPH	B-VP
O	1591	1601	expressing	express	VBG	B-NP
O	1602	1605	and	and	CC	I-NP
O	1606	1610	VEGF	VEGF	NN	I-NP
O	1610	1611	-	-	HYPH	B-NP
O	1611	1616	C156S	C156S	NN	I-NP
O	1616	1617	-	-	HYPH	O
O	1617	1627	expressing	express	VBG	B-VP
O	1628	1640	adenoviruses	adenovirus	NNS	B-NP
O	1640	1641	,	,	,	O
O	1642	1654	respectively	respectively	RB	B-ADVP
O	1654	1655	.	.	.	O

O	1656	1665	Cediranib	Cediranib	NN	B-NP
O	1666	1667	(	(	(	O
O	1667	1668	6	6	CD	B-NP
O	1669	1671	mg	mg	NN	I-NP
O	1671	1672	/	/	SYM	B-NP
O	1672	1674	kg	kg	NN	I-NP
O	1674	1675	/	/	SYM	B-NP
O	1675	1678	day	day	NN	I-NP
O	1678	1679	)	)	)	O
O	1680	1684	also	also	RB	B-ADVP
O	1685	1692	blocked	block	VBD	B-VP
O	1693	1705	angiogenesis	angiogenesis	NN	B-NP
O	1706	1709	and	and	CC	I-NP
O	1710	1727	lymphangiogenesis	lymphangiogenesis	NN	I-NP
O	1728	1735	induced	induce	VBN	B-VP
O	1736	1738	by	by	IN	B-PP
O	1739	1751	adenoviruses	adenovirus	NNS	B-NP
O	1752	1762	expressing	express	VBG	B-VP
O	1763	1767	VEGF	VEGF	NN	B-NP
O	1767	1768	-	-	HYPH	B-NP
O	1768	1769	A	A	NN	I-NP
O	1770	1772	or	or	CC	I-NP
O	1773	1777	VEGF	VEGF	NN	I-NP
O	1777	1778	-	-	HYPH	I-NP
O	1778	1779	C	C	NN	I-NP
O	1780	1783	and	and	CC	O
O	1784	1795	compromised	compromise	VBD	B-VP
O	1796	1799	the	the	DT	B-NP
B-Organism_substance	1800	1805	blood	blood	NN	I-NP
O	1806	1809	and	and	CC	O
B-Multi-tissue_structure	1810	1819	lymphatic	lymphatic	JJ	B-NP
I-Multi-tissue_structure	1820	1832	vasculatures	vasculature	NNS	I-NP
O	1833	1835	of	of	IN	B-PP
O	1836	1840	VEGF	VEGF	NN	B-NP
O	1840	1841	-	-	HYPH	B-NP
O	1841	1842	C	C	NN	I-NP
O	1842	1843	-	-	HYPH	O
O	1843	1853	expressing	express	VBG	B-VP
B-Cancer	1854	1860	tumors	tumor	NNS	B-NP
O	1860	1861	.	.	.	O

O	1862	1871	Cediranib	Cediranib	NN	B-NP
O	1872	1875	may	may	MD	B-VP
O	1875	1876	,	,	,	O
O	1877	1886	therefore	therefore	RB	B-ADVP
O	1886	1887	,	,	,	O
O	1888	1890	be	be	VB	B-VP
O	1891	1893	an	an	DT	B-NP
O	1894	1903	effective	effective	JJ	I-NP
O	1904	1909	means	mean	NNS	I-NP
O	1910	1912	of	of	IN	B-PP
O	1913	1923	preventing	prevent	VBG	B-VP
B-Cancer	1924	1929	tumor	tumor	NN	B-NP
O	1930	1941	progression	progression	NN	I-NP
O	1941	1942	,	,	,	O
O	1943	1946	not	not	RB	B-CONJP
O	1947	1951	only	only	RB	I-CONJP
O	1952	1954	by	by	IN	B-PP
O	1955	1965	inhibiting	inhibit	VBG	B-VP
O	1966	1971	VEGFR	VEGFR	NN	B-NP
O	1971	1972	-	-	HYPH	B-NP
O	1972	1973	2	2	CD	I-NP
O	1974	1982	activity	activity	NN	I-NP
O	1983	1986	and	and	CC	I-NP
O	1987	1999	angiogenesis	angiogenesis	NN	I-NP
O	1999	2000	,	,	,	O
O	2001	2004	but	but	CC	B-CONJP
O	2005	2009	also	also	RB	I-CONJP
O	2010	2012	by	by	IN	B-PP
O	2013	2026	concomitantly	concomitantly	RB	B-NP
O	2027	2037	inhibiting	inhibit	VBG	I-NP
O	2038	2043	VEGFR	VEGFR	NN	I-NP
O	2043	2044	-	-	HYPH	I-NP
O	2044	2045	3	3	CD	I-NP
O	2046	2054	activity	activity	NN	I-NP
O	2055	2058	and	and	CC	I-NP
O	2059	2076	lymphangiogenesis	lymphangiogenesis	NN	I-NP
O	2076	2077	.	.	.	O

